@article { author = {Mirjalili, Hamid and Amani, Hadis and Ismaili, Afsaneh and Milani Fard, Maryam and Abdolrazaghnejad, Ali}, title = {Evaluation of Drug Therapy in Non-Communicable Diseases; a Review Study}, journal = {Journal of Medicinal and Chemical Sciences}, volume = {5}, number = {2}, pages = {204-214}, year = {2022}, publisher = {Sami Publishing Company (SPC)}, issn = {2651-4702}, eissn = {2651-4702}, doi = {10.26655/JMCHEMSCI.2022.2.8}, abstract = {This study is a conceptual review. Various protocols have been proposed for non-communicable diseases worldwide. The importance of this large group of diseases has prompted the World Health Organization (WHO) to plan effectively to set targets to reduce mortality from these diseases by one-third by 2030 in the Sustainable Development Plan. In asthma, corticosteroids are still recognized as the most potent anti-asthma drugs, and there is still no drug with the same effect, and biological agents (drugs such as amalizumab) significantly improve the management of severe asthma. Regarding diabetes, the recommendations of the WHO were reviewed, and the first recommendation is that if metformin, which is recommended as the first oral antidiabetic drug in all guidelines, cannot control hyperglycemia, sulfonylurea should be prescribed to patients with type 2 diabetes. Non-communicable diseases in Iran cause 45% of the disease burden in men and 33% of the disease burden in women, of the total causes of the disease burden in both sexes (6-10). Obesity and overweight, arterial hypertension, inadequate physical activity and addiction are 86% of the risk factors for diseases and 11% of all diseases. These risk factors have caused 6.1 million years of adapted life expectancy in Iran.}, keywords = {Drug Therapy,non-communicable diseases,treatment}, url = {https://www.jmchemsci.com/article_140202.html}, eprint = {https://www.jmchemsci.com/article_140202_c26cc5bc2a59d2aa601eb0e7590ba766.pdf} }